BioSpace News Archive

Celgene Corporation (NASDAQ:CELG) reported net product sales of $4,024 million for the first quarter of 2019, a 14 percent increase from the same period in 2018

AlloSource®, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, celebrates 25 years of honoring donors and helping patients heal with an event featuring Columbine survivor and tissue recipient Kacey Ruegsegger Johnson.

Recent PRC study published by The Beryl Institute indicates that hospitals may not be getting feedback from a representative sample of patients to showcase caregiver efforts accurately

Researchers and scientists analyzing crystallized protein samples in life sciences and materials research can now benefit from the first commercially released integrated solution for performing micro electron diffraction (MicroED), an advanced technique that enables researchers to quickly resolve structures up to a billion times smaller than those needed using traditional methods.

Burlington Capital is launching a new venture in its aqueous ozone business by merging CleanCore Technologies and O-Z Tech Water.

Teva Pharmaceuticals USA, Inc. has initiated a voluntary recall in the United States, to the patient level, of 35 lots of bulk Losartan Potassium USP Tablets (6 lots of 25 mg strength and 29 lots of 100 mg strength).

Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) announces that additional data and analyses from its positive Phase 3 clinical trial of BARHEMSYS® (intravenous amisulpride) as a rescue treatment of established post-operative nausea & vomiting (PONV) will be presented today in a poster at the 2019 Annual Congress of Enhanced Recovery and Perioperative Medicine in Washington, DC

Alfa Chemistry launched to provide a wide range of carbon nanotube nanomaterials products to their customers, which include carbon nanotubes, purified single-wall carbon nanotubes, carbon nanotube sponges and oriented carbon nanotube array.

A new 10-point manifesto from a leading research institute is calling for action to speed up access to innovative cancer drugs as an accompanying survey of 1,000 cancer patients finds many face barriers in receiving the latest treatments.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced topline findings from the final analysis of the pivotal Phase 3 KEYNOTE-062 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy and in combination with chemotherapy (cisplatin and either 5-fluorouracil or capecitabine) for the first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma